Bovin Ann, Christensen Thomas Decker, Grove Erik Lerkevang
Ugeskr Laeger. 2017 Jul 17;179(29).
Atrial fibrillation (AF) is associated with a markedly increased risk of thromboembolic events, particularly in patients with valvular AF. Recent trials comparing vitamin K antagonists with non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in AF excluded most patients with valvular AF. Although the definition of valvular AF is disputed, the lack of evidence regarding the use of NOACs for these patients is not. We discuss the definition of valvular AF, the risk of thromboembolism, and the antithrombotic treatment for stroke prevention in these patients.
心房颤动（AF）与血栓栓塞事件风险显著增加相关，尤其是在瓣膜性房颤患者中。近期比较维生素K拮抗剂与非维生素K拮抗剂口服抗凝药（NOACs）用于房颤患者预防卒中的试验排除了大多数瓣膜性房颤患者。尽管瓣膜性房颤的定义存在争议，但关于NOACs用于这些患者缺乏证据这一点并无争议。我们讨论了瓣膜性房颤的定义、血栓栓塞风险以及这些患者预防卒中的抗栓治疗。
